POST LEONARD E 4
4 · CG Oncology, Inc. · Filed Oct 1, 2025
Insider Transaction Report
Form 4
POST LEONARD E
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-30$0.60/sh+5,000$3,000→ 5,000 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-09-30−5,000→ 119,077 totalExercise: $0.60Exp: 2028-07-08→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-09-30$40.09/sh−5,000$200,450→ 0 total
Footnotes (3)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Fully vested